- Field Trip Health Ltd. (FTRP) officially opens the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica
- The work at the new facility will leverage the research and development efforts that have been conducted by Field Trip at a temporary facility at UWI since January 2020
- The Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi will officially open on Tuesday, February 9 at 2 pm EST
- Field Trip is a global leader in the development and delivery of psychedelic therapies
- Field Trip (FTRP) is up 4.23 per cent and is trading at C$6.16 at 3:59 pm EST
Field Trip Health Ltd. (FTRP) officially opens the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica.
The research facility, which is opening as part of Field Trip’s previous partnership with the University of West Indies, is the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.
“Clinical studies on psilocybin and other plant-based psychedelic compounds have shown that they have great potential to produce profoundly positive changes in individuals, particularly those struggling from serious mental health conditions like anorexia, depression and PTSD,” said Dr. Nathan Bryson, Field Trip’s Chief Science Officer.
“With the opening of this facility, Field Trip and UWI will be leaders in the understanding of psilocybin-producing fungi and how they can be best utilized in a treatment setting,” added
The research will include broad-ranging topics from genetics, breeding and cultivation work on many of the 180+ plus recorded species of psilocybin-producing mushrooms to developing analytical methods for quality control.
The research will be led by Rupika Delgoda, Professor of Biochemical Pharmacology & Pharmacognosy and Director of the Natural Products Institute at UWI, who holds a D.Phil. from Oxford University (UK) in Pharmacology.
Pro-Vice-Chancellor and Principal at UWI, Mona, Professor Dale Webber added, “Field Trip has positioned itself as a global leader in the research and delivery of psychedelic-assisted psychotherapy.”
“We are confident that this state-of-the-art facility and partnership with Field Trip will foster a wealth of innovation for the future of mental health research and therapies, even as we contribute to the regulatory framework that the Government of Jamaica (GOJ) is currently developing,” concluded Webber.
Ronan Levy, Field Trip’s Executive Chairman, is looking forward to the new research and is optimistic about its future therapies.
“It is critical that we rigorously research, test and understand not only how they work in the body, but also how we can best produce these drugs and products and make available to those who need them where we are legally able to do so,” said Levy.
The Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi will officially open with a ceremony on Tuesday, February 9 at 2 pm EST.
The virtual ceremony will be broadcast live and feature remarks from Field Trip executives, representatives from the University of the West Indies.
It will also feature the Honorable Daryl Vaz, the Minister of Science, Energy and Technology of Jamaica.
Field Trip is a global leader in the development and delivery of psychedelic therapies.
Field Trip (FTRP) is up 4.23 per cent and is trading at C$6.16 at 3:59 pm EST.
